Zacks Research Brokers Decrease Earnings Estimates for ESPR
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at Zacks Research decreased their Q1 2025 EPS estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 25th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.19) for the quarter, down […]
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at Zacks Research decreased their Q1 2025 EPS estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, March 25th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.19) for the quarter, down […]
